Study Completed

Contraception, Heavy menstrual bleeding (HMB)

Bayer Identifier:

91391

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

2005-005001-37

EU CT Number:

Not Available

Qlaira: Inhib. of CYP3A4 by ketoconazole a. erythrom

Trial purpose

Please see attached Study Results Summary below

Key Participants Requirements

Sex

N/A

Age

45 - 75 Years

Trial summary

Enrollment Goal

Trial Dates

April 2006 - July 2006

Phase

Phase 1

Could I Receive a placebo

N/A

Products

Natazia/Qlaira (EV/DNG, BAY86-5027)

Accepts Healthy Volunteer

N/A

Where to participate

Status	Institution	Location
Completed	Bayer Pharma AG	Berlin, 13353, Germany

Trial design

Open-label, two-group, one-sequence, one-way crossover study to evaluate the effect of ketoconazole and erythromycin on the steady-state pharmacokinetics of SH T00658M (2 mg estradiol valerate and 3 mg dienogest) in healthy postmenopausal women

Trial Type

Interventional

Intervention Type

N/A

Trial Purpose

N/A

Allocation

N/A

Blinding

N/A

Assignment

N/A

Trial Arms

N/A

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.